PURPOSE: (186)Re displays abundant intermediate energy beta emission, and possesses an appropriate physical half-life of 3.7 days. We compared the efficacy of radioimmunotherapy (RIT) with an anti-colorectal cancer monoclonal IgG1, (186)Re-A7, with that of RIT employing (131)I in a mouse liver metastasis model. METHODS: Liver metastases were established by intrasplenic injection of LS180 human colon cancer cells. Based on the results of toxicity assessment with escalated administration doses, 21 MBq (186)Re-A7 and 7 MBq (131)I-A7 were chosen as maximum tolerated doses. In the first experiment, mice underwent RIT at 2 weeks when metastases attain a diameter of several millimeters, and were killed 2 weeks later to assess metastatic burden in the liver. In the second experiment, RIT was conducted at 1 week when metastases of several hundred micrometers in diameter were observed, and survival of mice was examined. RESULTS: (186)Re-A7 RIT inhibited the growth of liver metastases better than (131)I-A7 RIT ( P<0.02). Furthermore, (186)Re-A7 RIT induced better improvement in survival of mice than (131)I-A7 RIT ( P<0.002). (186)Re-A7 RIT caused slightly more severe myelotoxicity in mice, but they eventually recovered. Radiation dose estimation demonstrated a significant advantage of (186)Re-A7 RIT over (131)I-A7 RIT. CONCLUSION: These results support the use of RIT with (186)Re-MAb in an adjuvant setting in cases involving minimal disease.
PURPOSE: (186)Re displays abundant intermediate energy beta emission, and possesses an appropriate physical half-life of 3.7 days. We compared the efficacy of radioimmunotherapy (RIT) with an anti-colorectal cancer monoclonal IgG1, (186)Re-A7, with that of RIT employing (131)I in a mouse liver metastasis model. METHODS:Liver metastases were established by intrasplenic injection of LS180 humancolon cancer cells. Based on the results of toxicity assessment with escalated administration doses, 21 MBq (186)Re-A7 and 7 MBq (131)I-A7 were chosen as maximum tolerated doses. In the first experiment, mice underwent RIT at 2 weeks when metastases attain a diameter of several millimeters, and were killed 2 weeks later to assess metastatic burden in the liver. In the second experiment, RIT was conducted at 1 week when metastases of several hundred micrometers in diameter were observed, and survival of mice was examined. RESULTS: (186)Re-A7 RIT inhibited the growth of liver metastases better than (131)I-A7 RIT ( P<0.02). Furthermore, (186)Re-A7 RIT induced better improvement in survival of mice than (131)I-A7 RIT ( P<0.002). (186)Re-A7 RIT caused slightly more severe myelotoxicity in mice, but they eventually recovered. Radiation dose estimation demonstrated a significant advantage of (186)Re-A7 RIT over (131)I-A7 RIT. CONCLUSION: These results support the use of RIT with (186)Re-MAb in an adjuvant setting in cases involving minimal disease.
Authors: N Sato; T Saga; H Sakahara; Z Yao; Y Nakamoto; M Zhang; M Kuroki; Y Matsuoka; Y Iida; J Konishi Journal: J Nucl Med Date: 1999-04 Impact factor: 10.057
Authors: S Kinuya; A Kawashima; K Yokoyama; M Kudo; Y Kasahara; N Watanabe; N Shuke; H Bunko; T Michigishi; N Tonami Journal: Eur J Nucl Med Date: 2001-09
Authors: T M Behr; R M Sharkey; M E Juweid; R M Dunn; Z Ying; C H Zhang; J A Siegel; D M Goldenberg Journal: J Nucl Med Date: 1997-03 Impact factor: 10.057
Authors: R D Blumenthal; R M Sharkey; L Haywood; A M Natale; G Y Wong; J A Siegel; S J Kennel; D M Goldenberg Journal: Cancer Res Date: 1992-11-01 Impact factor: 12.701
Authors: S Kinuya; K Yokoyama; H Tega; T Hiramatsu; S Konishi; W Yamamoto; N Shuke; T Aburano; N Watanabe; T Takayama; T Michigishi; N Tonami Journal: Jpn J Cancer Res Date: 1998-08
Authors: Ali Azhdarinia; David J Yang; Dong-Fang Yu; Richard Mendez; Changsok Oh; Saady Kohanim; Jerry Bryant; E Edmund Kim Journal: Pharm Res Date: 2005-05-17 Impact factor: 4.200